Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

“Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed ... via LillyPlus will not change as we tenaciously pursue options ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Limiting therapeutic options not only restricts access to care ... To ensure that Canada does not become a global outlier in the treatment of atopic dermatitis and for the benefit of patients, Lilly ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the 7th China International Import Expo ...